Polidocanol Plus Glucose Versus Glucose Alone for the Treatment of Telangiectasias: Triple Blind, Randomised Controlled Trial (PG3T)

ObjectiveThe aim of this study was to compare the effectiveness and safety two sclerosing agents used treat telangiectasias in lower limbs: 0.2% polidocanol + 70% hypertonic glucose (HG) vs. 75% HG alone.MethodsA prospective, randomised, triple blind, controlled, parallel group trial with patients randomly assigned a 1:1 ratio between January December 2015, month follow up, from single academic medical centre Brazil, carried out. Participants were women aged 18–65 years on lateral aspect one thigh, classified as C1EpAsPn who underwent sclerotherapy session or alone an area limited by rectangular template. The primary endpoint elimination within 60 days pre-treatment pattern. length vessels measured images obtained before after treatment using ImageJ software. Safety outcomes analysed immediately, 7 days, treatment, included pigmentation.ResultsA total 115 included, 98 whom completed study. Sclerotherapy significantly more effective than target (82.2% 63.9%; p < .001); considering minimum improvement 75%, there 0.49 risk reduction (95% confidence interval 0.24–0.98; = .047). No severe adverse events occurred either group. Pigmentation most common minor event shorter treated (median 0 cm 0.5 cm, respectively; .033).ConclusionPolidocanol plus had better results telangiectasias. occurred. both groups HG. alone. A pigmentation. .033). Polidocanol